UBS Group Lowers Zimmer Biomet (NYSE:ZBH) Price Target to $88.00

Zimmer Biomet (NYSE:ZBH) had its price target cut by analysts at UBS Group from $96.00 to $88.00 in a report issued on Thursday,Benzinga reports. The firm currently has a “sell” rating on the medical equipment provider’s stock. UBS Group’s price target suggests a potential downside of 0.01% from the company’s previous close.

Several other equities analysts also recently commented on the company. Redburn Partners set a $130.00 target price on Zimmer Biomet in a research report on Thursday, September 18th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $100.00 price objective (down previously from $115.00) on shares of Zimmer Biomet in a report on Thursday. Roth Capital reiterated a “buy” rating on shares of Zimmer Biomet in a research report on Thursday, August 7th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, October 8th. Finally, Royal Bank Of Canada cut their price target on shares of Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating on the stock in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $109.42.

Zimmer Biomet Price Performance

ZBH stock traded up $0.46 during trading on Thursday, reaching $88.01. 2,197,702 shares of the company were exchanged, compared to its average volume of 1,922,379. The company has a market capitalization of $17.43 billion, a price-to-earnings ratio of 21.36, a P/E/G ratio of 2.29 and a beta of 0.67. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. The company has a 50-day moving average of $100.84 and a two-hundred day moving average of $97.60. Zimmer Biomet has a twelve month low of $85.33 and a twelve month high of $114.72.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The firm had revenue of $2 billion for the quarter, compared to analysts’ expectations of $2.01 billion. During the same quarter in the previous year, the firm posted $1.74 earnings per share. The company’s revenue was up 9.6% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities analysts predict that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Insider Activity at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,500 shares of the company’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the sale, the senior vice president owned 6,833 shares in the company, valued at $711,656.95. This represents a 18.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.39% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Zimmer Biomet

A number of hedge funds have recently bought and sold shares of ZBH. Key Financial Inc boosted its stake in shares of Zimmer Biomet by 164.6% in the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 163 shares during the last quarter. Cullen Frost Bankers Inc. boosted its holdings in shares of Zimmer Biomet by 66.7% in the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 116 shares during the last quarter. Cary Street Partners Investment Advisory LLC grew its position in Zimmer Biomet by 83.7% during the second quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 149 shares during the period. Root Financial Partners LLC bought a new position in Zimmer Biomet during the third quarter valued at about $31,000. Finally, Accent Capital Management LLC bought a new stake in Zimmer Biomet in the first quarter worth about $35,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.